Compare Novartis AG (NVS) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs BlackRock TCP Capital Corp — how do they compare? Novartis AG trades at $143.2 (market cap $268.57B), while BlackRock TCP Capital Corp trades at $3.99 (market cap $337.71M). The key difference: Novartis AG is far larger — about 795.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.88%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and BlackRock TCP Capital Corp for 88 Days on average.
| NVS | TCPC | |
|---|---|---|
Market Cap | $268.57B | $337.71M |
Volume | 1,532,573 | 436,109 |
Sector | Health | Financials |
52-Week High | $168.62 | $6.20 |
52-Week Low | $121.80 | $3.13 |
Typical Hold Time | 82 Days | 88 Days |
Enterprise Value | $309.89B | $1.09B |
Dividend Yield | 3.31% | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
TCPC trades at $4.01, up 1.78% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.22 per share, beating expectations, and announced a $523 million portfolio sale to reduce leverage. However, revenue and net income remain negative, with a net income margin of 118.75% in 2026 indicating significant losses relative to revenue. The stock is trading below book value with a P/B of 0.61.
The outlook is mixed: strategic actions like portfolio sales may improve financial health, but persistent negative earnings and a class action lawsuit pose risks. Analyst sentiment is cautious with a 30.77% buy rating. Investors should weigh the potential for operational turnaround against ongoing profitability challenges and legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
